Jennifer Zachary Merck & Co., Inc. (MRK) insider trading activity

Jennifer Zachary is EVP, General Counsel of Merck & Co., Inc.. Currently has a direct ownership of 55,285 shares of MRK, which is worth approximately $5.47 Million. The most recent transaction as insider was on Jan 27, 2025, when has been sold 25,423 shares (Common Stock) at a price of $97.94 per share, resulting in proceeds of $2,489,928. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 55.3K

90.26% 3M change

6.52% 12M change

Total Value Held $5.47 Million

Jennifer Zachary Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 27 2025	BUY Grant, award, or other acquisition	$2,489,928 $97.94 p/Share	25,423 Added 31.5%	55,285 Common Stock
Feb 02 2024	SELL Open market or private sale	$6,284,888 $126.97 p/Share	49,499 Reduced 63.01%	29,057 Common Stock
Feb 02 2024	BUY Exercise of conversion of derivative security	$1,691,220 $87.1 p/Share	19,417 Added 19.82%	78,556 Common Stock
Jan 22 2024	BUY Grant, award, or other acquisition	$2,782,480 $119.43 p/Share	23,298 Added 28.26%	59,139 Common Stock
May 04 2023	SELL Open market or private sale	$2,250,790 $117.59 p/Share	19,141 Reduced 35.27%	35,127 Common Stock
Feb 03 2023	SELL Open market or private sale	$7,782,732 $103.17 p/Share	75,436 Reduced 58.32%	53,919 Common Stock
Feb 03 2023	BUY Exercise of conversion of derivative security	$4,227,433 $56.04 p/Share	75,436 Added 36.84%	129,355 Common Stock
Jan 23 2023	BUY Grant, award, or other acquisition	$1,717,534 $109.88 p/Share	15,631 Added 22.47%	53,919 Common Stock
Oct 28 2022	SELL Open market or private sale	$16,436,262 $99.46 p/Share	165,255 Reduced 81.29%	38,040 Common Stock
Oct 28 2022	BUY Exercise of conversion of derivative security	-	148,647 Added 42.24%	203,295 Common Stock
Feb 24 2022	BUY Grant, award, or other acquisition	$1,354,054 $73.51 p/Share	18,420 Added 25.64%	53,419 Common Stock
May 04 2021	SELL Payment of exercise price or tax liability	$216,011 $75.98 p/Share	2,843 Reduced 7.69%	34,140 Common Stock
May 04 2021	BUY Exercise of conversion of derivative security	$438,557 $75.98 p/Share	5,772 Added 13.5%	36,983 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$1,757,331 $72.62 p/Share	24,199 Added 43.88%	30,947 Common Stock
May 04 2020	SELL Payment of exercise price or tax liability	$220,816 $77.67 p/Share	2,843 Reduced 29.96%	6,646 Common Stock
May 04 2020	BUY Exercise of conversion of derivative security	$448,311 $77.67 p/Share	5,772 Added 37.82%	9,489 Common Stock
May 04 2019	SELL Payment of exercise price or tax liability	$172,320 $80.0 p/Share	2,154 Reduced 37.32%	3,618 Common Stock
May 04 2019	BUY Exercise of conversion of derivative security	-	5,772 Added 50.0%	5,772 Common Stock

Also insider at

RGNX

REGENXBIO Inc. Healthcare